1. TeijaroJR, WalshKB, CahalanS, FremgenDM, RobertsE, et al. (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146: 980–991.
2. JewellNA, ClineT, MertzSE, SmirnovSV, FlanoE, et al. (2010) Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 84: 11515–11522.
3. KumagaiY, TakeuchiO, KatoH, KumarH, MatsuiK, et al. (2007) Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 27: 240–252.
4. KobasaD, JonesSM, ShinyaK, KashJC, CoppsJ, et al. (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319–323.
5. IwasakiA, MedzhitovR (2011) A new shield for a cytokine storm. Cell 146: 861–862.
6. KellyC, KlenermanP, BarnesE (2011) Interferon lambdas: the next cytokine storm. Gut 60: 1284–1293.
7. MordsteinM, NeugebauerE, DittV, JessenB, RiegerT, et al. (2010) Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84: 5670–5677.
8. SheppardP, KindsvogelW, XuW, HendersonK, SchlutsmeyerS, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63–68.
9. KotenkoSV, GallagherG, BaurinVV, Lewis-AntesA, ShenM, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77.
10. IversenMB, PaludanSR (2010) Mechanisms of type III interferon expression. J Interferon Cytokine Res 30: 573–578.
11. OkabayashiT, KojimaT, MasakiT, YokotaS, ImaizumiT, et al. (2011) Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 160: 360–366.
12. PottJ, MahlakoivT, MordsteinM, DuerrCU, MichielsT, et al. (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108: 7944–7949.
13. QiuX, GuoG, ChenK, KashiwadaM, DrukerBJ, et al. (2012) A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia 14: 547–558.
14. ZhangJG, FarleyA, NicholsonSE, WillsonTA, ZugaroLM, et al. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 96: 2071–2076.
15. UngureanuD, SaharinenP, JunttilaI, HiltonDJ, SilvennoinenO (2002) Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22: 3316–3326.
16. WaibociLW, AhmedCM, MujtabaMG, FlowersLO, MartinJP, et al. (2007) Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol 178: 5058–5068.
17. PauliEK, SchmolkeM, WolffT, ViemannD, RothJ, et al. (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog 4: e1000196.
18. PothlichetJ, ChignardM, Si-TaharM (2008) Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. J Immunol 180: 2034–2038.
19. JiaD, RahbarR, ChanRW, LeeSM, ChanMC, et al. (2010) Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One 5: e13927.
20. UetaniK, HiroiM, MeguroT, OgawaH, KamisakoT, et al. (2008) Influenza A virus abrogates IFN-gamma response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur J Immunol 38: 1559–1573.
21. BrandS, ZitzmannK, DambacherJ, BeigelF, OlszakT, et al. (2005) SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 331: 543–548.
22. WangS, LiH, ChenY, WeiH, GaoGF, et al. (2012) Transport of influenza virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42 proteins. J Biol Chem 287: 9804–9816.
23. WangJP, BowenGN, PaddenC, CernyA, FinbergRW, et al. (2008) Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 112: 2028–2034.
24. BenderA, BuiLK, FeldmanMA, LarssonM, BhardwajN (1995) Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med 182: 1663–1671.
25. PichlmairA, SchulzO, TanCP, NaslundTI, LiljestromP, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314: 997–1001.
26. HornungV, EllegastJ, KimS, BrzozkaK, JungA, et al. (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314: 994–997.
27. KatoH, SatoS, YoneyamaM, YamamotoM, UematsuS, et al. (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19–28.
28. SommereynsC, PaulS, StaeheliP, MichielsT (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017.
29. PoatB, HazariS, ChandraPK, GunduzF, BalartLA, et al. (2010) SH2 modified STAT1 induces HLA-I expression and improves IFN-gamma signaling in IFN-alpha resistant HCV replicon cells. PLoS One 5: e13117.
30. LiddleFJ, AlvarezJV, PoliV, FrankDA (2006) Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 45: 5599–5605.
31. OnoguchiK, YoneyamaM, TakemuraA, AkiraS, TaniguchiT, et al. (2007) Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282: 7576–7581.
32. KobasaD, TakadaA, ShinyaK, HattaM, HalfmannP, et al. (2004) Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431: 703–707.
33. GarciaCC, RussoRC, GuabirabaR, FagundesCT, PolidoroRB, et al. (2010) Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice. PLoS Pathog 6: e1001171.
34. Le GofficR, LeymarieO, ChevalierC, ReboursE, Da CostaB, et al. (2011) Transcriptomic analysis of host immune and cell death responses associated with the influenza A virus PB1-F2 protein. PLoS Pathog 7: e1002202.
35. LuD, MaY, ZhangW, BaoD, DongW, et al. (2012) Knockdown of cytochrome P450 2E1 inhibits oxidative stress and apoptosis in the cTnT(R141W) dilated cardiomyopathy transgenic mice. Hypertension 60: 81–89.
36. YangJ, WangJ, ChenK, GuoG, XiR, et al. (2013) eIF4B phosphorylation by Pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res 73: 4898–4908.
37. McKennaK, BeignonAS, BhardwajN (2005) Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79: 17–27.
38. TakeuchiO, AkiraS (2009) Innate immunity to virus infection. Immunol Rev 227: 75–86.
39. La GrutaNL, KedzierskaK, StambasJ, DohertyPC (2007) A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 85: 85–92.
40. MarukianS, AndrusL, SheahanTP, JonesCT, CharlesED, et al. (2011) Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology 54: 1913–1923.
41. LiJ, HuS, ZhouL, YeL, WangX, et al. (2011) Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia 59: 58–67.
42. SvetlikovaD, KabatP, OhradanovaA, PastorekJ, BetakovaT (2010) Influenza A virus replication is inhibited in IFN-lambda2 and IFN-lambda3 transfected or stimulated cells. Antiviral Res 88: 329–333.
43. WangJ, Oberley-DeeganR, WangS, NikradM, FunkCJ, et al. (2009) Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection. J Immunol 182: 1296–1304.
44. KimuraA, NakaT, NakahamaT, ChinenI, MasudaK, et al. (2009) Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 206: 2027–2035.
45. ShenH, LentschAB (2004) Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 286: C840–847.
46. WangY, WuTR, CaiS, WelteT, ChinYE (2000) Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol Cell Biol 20: 4505–4512.
47. AustenaaLM, CarlsenH, HollungK, BlomhoffHK, BlomhoffR (2009) Retinoic acid dampens LPS-induced NF-kappaB activity: results from human monoblasts and in vivo imaging of NF-kappaB reporter mice. J Nutr Biochem 20: 726–734.
48. KramerOH, BausD, KnauerSK, SteinS, JagerE, et al. (2006) Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20: 473–485.
49. StrebovskyJ, WalkerP, LangR, DalpkeAH (2011) Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. FASEB J 25: 863–874.
50. DaiX, SayamaK, YamasakiK, TohyamaM, ShirakataY, et al. (2006) SOCS1-negative feedback of STAT1 activation is a key pathway in the dsRNA-induced innate immune response of human keratinocytes. J Invest Dermatol 126: 1574–1581.
51. FanK, JiaY, WangS, LiH, WuD, et al. (2012) Role of Itk signalling in the interaction between influenza A virus and T-cells. J Gen Virol 93: 987–997.
52. AhmedCM, DabelicR, WaibociLW, JagerLD, HeronLL, et al. (2009) SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J Virol 83: 1402–1415.
53. GuoG, QiuX, WangS, ChenY, RothmanPB, et al. (2010) Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 29: 3845–3853.
54. ZitzmannK, BrandS, De ToniEN, BaehsS, GokeB, et al. (2007) SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67: 5025–5032.
55. HuangFJ, SteegPS, PriceJE, ChiuWT, ChouPC, et al. (2008) Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 68: 9634–9642.
56. ShenL, Evel-KablerK, StrubeR, ChenSY (2004) Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22: 1546–1553.
57. JiangLJ, ZhangNN, DingF, LiXY, ChenL, et al. (2011) RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci U S A 108: 1897–1902.
58. DelaloyeJ, RogerT, Steiner-TardivelQG, Le RoyD, Knaup ReymondM, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5: e1000480.
59. ReedLJ, MuenchH (1938) A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 27: 493–497.